Knight Therapeutics (TSE:GUD) Hits New 12-Month High - Should You Buy?

Key Points

• Knight Therapeutics shares hit a new 52-week high of C$6.48, closing slightly lower at C$6.45 with a trading volume of 94,534 shares.
• Analysts from Canaccord Genuity set a new price target of C$6.50 for Knight Therapeutics, with a consensus rating of "Strong Buy" and an average price target of C$7.15.
• The company maintains a solid financial position with a current ratio of 3.36 and a debt-to-equity ratio of 7.52, although its P/E ratio stands at -21.23.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s share price reached a new 52-week high on Thursday . The company traded as high as C$6.48 and last traded at C$6.45, with a volume of 94534 shares trading hands. The stock had previously closed at C$6.29.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$6.50 price objective on Knight Therapeutics and gave the stock a "buy" rating in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Strong Buy" and an average price target of C$7.15.

Knight Therapeutics Stock Up 1.1%

The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The stock has a market capitalization of C$643.31 million, a P/E ratio of -21.23, a P/E/G ratio of -1,013.50 and a beta of 0.50. The stock's 50-day moving average price is C$6.01 and its two-hundred day moving average price is C$5.86.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.